PRV211 based on PRV™ platform, is an innovative system that employs cisplatin-loaded nanoparticles, meticulously designed to target, and eliminate remaining cancer cells following tumor resection and combat the body's healing response after surgery that can stimulate cancer cell proliferation.

PRV™ Platform Life Cycle

Examples of Solid tumors that can use PRV211
40% of all Chemotherapy Treatments Use Platinum Drugs

Why is PRV211 Needed?

- Currently, after tumor resection, approximately 6 to 8 weeks of wound healing is required prior to any further treatment
- During this time, there is a high chance of any residual cells to metastasize, accelerated by body's healing process and growth factors.
- According to American Cancer Society, despite the efficacy of primary treatment, leftover cancerous cells can continue to replicate in the body either at the initial tumor site or elsewhere
- Levels of immunosuppressive tumor-associated macrophages (TAMs) in the body post-surgery puts a person even at a bigger risk for cancer recurrence
- **PRV211 delivers highly potent cisplatin nanoparticles directly to the resected tumor bed, providing long lasting controlled release of the cytotoxic drug, aimed at eliminating tumor recurrence and micrometastases**

Privo technologies.

Tough On Cancer, Easy On Patients

PRV211 – Reduce the Chance of Tumor Recurrence

PRV211 can be easily applied to the resection bed to eliminate remaining cancer cells post Tumor Resection



Surgeons have a challenging balancing act: Cut out too much, damage functionality / remove too little, risk leaving tumor cells behind.

Introducing PRV211 : This patented treatment increases protection against cancer recurrence. The treatment is tailored specifically for solid tumor surgeries and is built upon the PRV™ platform. The platform is clinically proven safe and effective in a human study CLN-001.

PRV211 is aimed at enhancing outcomes and patient well-being.

Key Takeaways:

- **Development Stage:** PRV211 is a Phase 1/2 clinical ready asset
- **PRV Platform:** Employs the same nanoparticles derived from the clinically studied PRV111 patch with a customized matrix for surgical use. (PRV111 clinical study NCT03502148)
- **Initial indication:** Squamous cell Carcinoma in the Oral Cavity
- **Regulatory Plan:** Obtain initial market aproval in oral cavity cancer and rapidly expand to multiple intraoperative/surgical applications in oncology.
- **Patent Protected:** Issued patent for PRV211. Expires 2037

How Does PRV211 work?



- PRV211 is a novel system comprising a unique formulation, including nanoparticles which non-covalently interact with payloads to increase drug dispersion and diffusion when dosed/applied to resected tumor beds.
- PRV211 is applied directly onto the resected tumor bed and the properties of hydrogel matrix are bio adhesive so it will adhere to the resected tissue type.
- PRV211 is left in place for 10 minutes for the cisplatin loaded nanoparticles to penetrate below the tumor bed surface.
- After 10 minutes, treatment is complete, and surgery can continue.

Clinical Evidence: The PRV™ platform was clinically studied in PRV111's CLN-001 clinical trial. In the case of oral cavity cancer, Privo has clinically tested the topical patch (PRV111) embedded with cisplatin loaded nanoparticles in patients diagnosed with T1-T2 oral cancer.

100% reduction, Gum Tumor

Efficacy:
Tumor volume reduction: >70%,
Response rate: 87%

Safety:
No Dose Limiting Toxicities
No Systemic Toxicity
No Related Serious Adverse Events

PRV211 Nanoengineered Design Attributes

- **Enhanced safety & efficacy**
  - Provide controlled, localized sustained release
  - Protects volatile active drugs against rapid deactivation
  - Enhance penetration into resected tumor bed
  - Minimize systemic exposure
  - Reach and enter regional lymph nodes
  - Triggers antitumor immune response
  - High cell uptake and local retention

Immune Response

- The PRV™ platform was clinically studied in PRV111's CLN-001 clinical trial.
- Data showed a high degree of immunogenesis/immunomodulation as demonstrated by staining for tumor infiltrating lymphocytes.
- PRV™ platform cisplatin loaded nanoparticles immunomodulation properties can increase the treatment's durability



What's next? fundraising for PRV211 Phase 1/2 clinical trial.

Visit www.Privotechnologies.com to watch a short video about Privo's mission to be "Tough on Cancer, Easy on Patients".